IMO 2125 + ribavirin versus peginterferon alfa-2a + ribavirin in patients with hepatitis C stratified for IL28B genotype.

Trial Profile

IMO 2125 + ribavirin versus peginterferon alfa-2a + ribavirin in patients with hepatitis C stratified for IL28B genotype.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2012

At a glance

  • Drugs IMO 2125; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Feb 2012 Actual end date 20 Jan 2012 added as reported by EudraCT.
    • 25 Feb 2012 Status changed from suspended to discontinued as reported by EudraCT.
    • 10 May 2011 Actual initiation date 8 Apr 2011 added, trial location Hungary added as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top